Development and Characterization of a Solid Dispersion of an Anti-Diabetic Drug Using Pectin as a Natural Polymer

Year : 2026 | Volume : 17 | 02 | Page :
    By

    Atul Sahu,

  • Pawan Kumar,

  1. Associate Professor, Department of Pharmacy, Chandra Shekhar Singh College of Pharmacy, Kaushambi, Uttar Pradesh, India
  2. Associate Professor, Department of Pharmacy, Chandra Shekhar Singh College of Pharmacy, Kaushambi, Uttar Pradesh, India

Abstract

Aim: The current study sought to improve the solubility and oral bioavailability of gliclazide by creating solid dispersions and oral dispersible tablets (ODTs) with enhanced physicochemical characteristics and maintained antidiabetic action. Methods: Preformulation studies were conducted to evaluate the physicochemical properties of gliclazide, including physical appearance, melting point, solubility, and partition coefficient. Solid dispersions were prepared using hydrophilic carriers-pectin and PVP K30, and subsequently characterized by Fourier Transform Infrared Spectroscopy and X-Ray Diffraction analysis. The in vitro antidiabetic efficacy of the formulations was assessed through α-amylase and α-glucosidase inhibition assays. Additionally, in vitro dissolution profiles were evaluated. Stability studies were performed in accordance with ICH guidelines over six months. Results: Gliclazide was observed as a white crystalline powder with melting point of 173°C, confirming purity. It showed poor aqueous solubility (0.015-0.020 mg/mL) at physiological pH ranges and moderate lipophilicity (logP 1.82), which justified the solid dispersion formulation with pectin and PVP K30. The optimization of formulation F3 showed enhanced in vitro antidiabetic activity with 49.2% and 57.5% of α-amylase and α-glucosidase, respectively. Physical and chemicals integrity of the formulation was maintained through six months of ICH recommended conditions, confirmed by stability studies, supporting its commercial potential. Conclusion: Solid dispersion-based ODTs offer an effective approach to improving the solubility, formulation performance, and therapeutic potential of Gliclazide. Formulation F3 emerged as the optimized candidate with superior physicochemical properties, antidiabetic activity, and stability.

Keywords: Gliclazide; Oral dispersible tablets; Solid dispersion; Solubility enhancement; Antidiabetic activity; Stability studies

How to cite this article:
Atul Sahu, Pawan Kumar. Development and Characterization of a Solid Dispersion of an Anti-Diabetic Drug Using Pectin as a Natural Polymer. Research and Reviews: A Journal of Pharmaceutical Science. 2026; 17(02):-.
How to cite this URL:
Atul Sahu, Pawan Kumar. Development and Characterization of a Solid Dispersion of an Anti-Diabetic Drug Using Pectin as a Natural Polymer. Research and Reviews: A Journal of Pharmaceutical Science. 2026; 17(02):-. Available from: https://journals.stmjournals.com/rrjops/article=2026/view=242725


References

1. American Diabetes Association. (2022). Classification and diagnosis of diabetes: Standards of medical care in diabetes—2022. Diabetes Care, 45(Supplement 1), S17–S38.
2. Amidon, G. L., Lennernäs, H., Shah, V. P., and Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3), 413–420.
3. Babu, P. R., Babu, K. N., and Rao, P. L. (2010). Formulation and evaluation of solid dispersions of glibenclamide. International Journal of Pharmaceutical Sciences and Research, 1(8), 57–63.
4. Baka, E., Comer, J. E., and Takács-Novák, K. (2008). Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. Journal of Pharmaceutical and Biomedical Analysis, 46(2), 335–341.
5. DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., … and Weiss, R. (2015). Type 2 diabetes mellitus. Nature Reviews Disease Primers, 1(1), 1–22.
6. Di, L., Fish, P. V., and Mano, T. (2012). Bridging solubility between drug discovery and development. Drug Discovery Today, 17(9-10), 486–495.
7. Febriyenti, F., Rahmi, S., & Halim, A. (2019). Study of gliclazide solid dispersion systems using PVP K-30 and PEG 6000 by solvent method. Journal of Pharmacy and Bioallied Sciences, 11(3), 262–267.
8. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). Stability testing of new drug substances and products Q1A(R2). ICH Harmonised Tripartite Guideline.
9. International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). Brussels, Belgium: International Diabetes Federation.
10. Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., and Onoue, S. (2011). Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. International Journal of Pharmaceutics, 420(1), 1–10.
11. Knip, M., and Siljander, H. (2016). The role of the environmental factors in type 1 diabetes mellitus. Endocrine Development, 31, 102–119.
12. Leo, A., Hansch, C., and Elkins, D. (1971). Partition coefficients and their uses. Chemical Reviews, 71(6), 525–616.
13. Lipinski, C. A. (2002). Poor aqueous solubility—An industry wide problem in drug discovery. American Pharmaceutical Review, 5(3), 82–85.
14. Liu, Y., Sun, C., Hao, Y., Jiang, T., Zheng, L., and Wang, S. (2013). Nanotechnology-based drug delivery systems for poorly water-soluble drugs. Asian Journal of Pharmaceutical Sciences, 8(6), 319–329.
15. Loftsson, T., and Brewster, M. E. (2010). Pharmaceutical applications of cyclodextrins: Basic science and product development. Journal of Pharmacy and Pharmacology, 62(11), 1607–1621.
16. Maggi, L., Bruni, G., and Maietta, M. (2015). Improvement of the dissolution behavior of gliclazide, a slightly soluble drug, using solid dispersions. Journal of Drug Delivery Science and Technology, 26, 17–23
17. Nathi, R., Ketha, N. V. D. P., Kowtarapu, L. P., Muchakayala, S. K., Konduru, N., Saroja, B., and Marisetti, A. L. (2023). Flurbiprofen cataplasms: Development and validation of in-vitro dissolution methods and evaluation of multimedia dissolution profiles. Pharmaceutical Science Advances, 1(2), 100018. https://doi.org/10.1016/j.pscia.2023.100018
18. Patel, R. P., Patel, M. P., and Suthar, A. M. (2014). Solid dispersions: A promising approach for solubility enhancement. International Journal of Pharmaceutical Sciences Review and Research, 26(2), 113–120.
19. Patil, S. V., & Kumar, L. (2023). Development and evaluation of solid dispersion-based oral dispersible tablets of Gliclazide for enhanced antidiabetic potential. Journal of Pharmaceutical Sciences and Innovation, 12(4), 245-253.
20. Pouton, C. W. (2006). Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. European Journal of Pharmaceutical Sciences, 29(3-4), 278–287.
21. Prajapati, S. K., and Patel, M. R. (2010). Formulation and evaluation of glibenclamide solid dispersions. Journal of Pharmaceutical and Scientific Innovation, 1(2), 45–50.
22. Rajamma, A. J., Sateesha, S. B., Narode, M. K., Prashanth, V. R. S. S., & Karthik, A. M. (2015). Preparation and crystallographic analysis of gliclazide polymorphs. Indian Journal of Pharmaceutical Sciences, 77(1), 34–40.
23. Remko, M. (2009). Theoretical study of molecular structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some hypoglycemic agents. Journal of Molecular Structure: THEOCHEM, 897(1–3), 73–82.
24. Sangster, J. (1997). Octanol-water partition coefficients: Fundamentals and physical chemistry. John Wiley and Sons
25. Savjani, K. T., Gajjar, A. K., and Savjani, J. K. (2012). Drug solubility: Importance and enhancement techniques. ISRN Pharmaceutics, 2012, 195727.
26. Seedher, N., and Kanojia, M. (2009). Co-solvent solubilization of some poorly-soluble antidiabetic drugs. Pharmaceutical Development and Technology, 14(2), 185–192.
27. Singh, I., Kaur, L., and Rana, V. (2017). Natural polymers in drug delivery: A review. International Journal of Pharmaceutical Sciences and Research, 8(4), 1435–1445.
28. Sweetman, S. C. (Ed.). (2009). Martindale: The complete drug reference (36th ed.). Pharmaceutical Press.
29. Wassvik, C. M., Holmén, A., Bergström, C. A. S., Zamora, I., and Artursson, P. (2006). Contribution of solid-state properties to the aqueous solubility of drugs. European Journal of Pharmaceutical Sciences, 29(3-4), 294-305. https://doi.org/10.1016/j.ejps.2006.05.013
30. World Health Organization. (2022). Diabetes fact sheet. Geneva: World Health Organization.
31. Young, S. H., Ye, J., Frazer, D. G., Shi, X., and Castranova, V. (2008). Molecular mechanism of tumor necrosis factor-α production in 1→3-β-glucan (zymosan)-activated macrophages. Journal of Biological Chemistry, 283(22), 15095–15104.

Ahead of Print Subscription Original Research
Volume 17
02
Received 19/02/2026
Accepted 01/05/2026
Published 03/05/2026
Publication Time 73 Days
1

Login


My IP

PlumX Metrics